MYGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
190.7M
-4.8%
200.4M
-4.5%
209.8M
+2.0%
205.7M
-3.5%
213.1M
Cost of Revenue
63.7M
+1.4%
62.8M
-0.3%
63.0M
+1.8%
61.9M
+1.0%
61.3M
Gross Profit
127.0M
-7.7%
137.6M
-6.3%
146.8M
+2.1%
143.8M
-5.3%
151.8M
Operating Expenses
165.9M
-1.4%
168.3M
+10.4%
152.5M
-8.7%
167.1M
-65.3%
481.0M
R&D
25.0M
-7.7%
27.1M
+6.3%
25.5M
-9.6%
28.2M
+10.2%
25.6M
SG&A
140.9M
+3.8%
135.8M
+9.3%
124.3M
-10.5%
138.9M
+0.1%
138.7M
Operating Income
-38900000
-26.7%
-30700000
-438.6%
-5700000
+75.5%
-23300000
+92.9%
-329200000
EBITDA
-26400000
-106.3%
-12800000
-233.3%
9.6M
+189.7%
-10700000
-768.8%
1.6M
Net Income
-43200000
-26.7%
-34100000
-331.6%
-7900000
+71.2%
-27400000
+91.7%
-330500000
EPS (Basic)
$-0.46
-27.8%
$-0.36
-350.0%
$-0.08
+72.4%
$-0.29
+91.9%
$-3.57
EPS (Diluted)
$-0.46
-27.8%
$-0.36
-350.0%
$-0.08
+72.4%
$-0.29
+91.9%
$-3.57
Shares (Diluted)
94.8M
+1.2%
93.7M
+0.3%
93.4M
+0.3%
93.1M
+0.6%
92.5M
Myriad Genetics (MYGN) โ€” Financials